Hong Kong-listed China Resources Pharmaceutical Group Limited (CHINARES PHARMA, 03320) reported that its consolidated subsidiary Dong-E-E-Jiao released unaudited results for the six months ended 30 June 2026. The Group effectively controls 23.66% of Dong-E-E-Jiao, which is accounted for as a subsidiary.

Revenue and Profitability • Dong-E-E-Jiao generated revenue of RMB 3.16 billion, up 3.39% year on year. • Net profit attributable to shareholders reached RMB 860.38 million, a 5.66% increase. • Core net profit (excluding extraordinary items) grew 4.56% to RMB 819.87 million. • Basic and diluted EPS both rose to RMB 1.34, compared with RMB 1.26 a year earlier. • Weighted average ROE improved 0.43 ppt to 8.12%.

Balance-Sheet Movements • Total assets declined 5.04% to RMB 12.71 billion from RMB 13.38 billion at end-2025. • Net assets attributable to shareholders edged down 1.72% to RMB 10.16 billion.

Cash Flow • Net cash generated from operating activities fell sharply to RMB 81.57 million, down 91.56% from RMB 966.24 million in the prior-year period.

Dividend Proposal • The board of Dong-E-E-Jiao has proposed an interim cash dividend of RMB 13.44 (tax inclusive) per 10 shares, subject to shareholder approval at the 2026 AGM.

Audit Status The interim figures are prepared under PRC GAAP and remain unaudited; adjustments may arise upon completion of the audit process.

Investors are advised to refer to the full interim report available on the Shenzhen Stock Exchange website for comprehensive details.